This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2026
Grand Nikko Tokyo DaibaTokyo
Menu
keyboard_arrow_right

Main Conference Day 3

keyboard_arrow_leftSearch & Filter
search
Main Conference Day 3
search
8:00am - 8:10am
Registration and Coffee
Plenary Session
Showing 1 of 1 Streams
8:10am - 8:15am
Chairperson’s Remarks: Plenary Day 3
  • Yogesh Sanghvi, PhD - President, Rasayan Inc.
8:15am - 8:45am
Lipid Nanoparticles for mRNA Vaccine Delivery
  • Mate Vadovics, PhD - Postdoctoral Fellow, Norbert Pardi Lab, University of Pennsylvania
8:45am - 9:15am
LEAD (Ligand- and Enhancer-Assisted Delivery) Enables Efficient siRNA Delivery to Immune Cells by Targeting a Cell Type-Specific Receptors
  • Weimin Wang, PhD - Founder & CEO, Sanegene Bio
9:15am - 9:45am
Phase 1 Clinical Testing of a First-in-Class ASO Therapeutic against Metastatic Cancer
  • Zdravka Medarova, PhD - Co-Founder and Chief Scientific Officer, TransCode Therapeutics
9:45am - 10:15am
Targeting lncRNA TUG1 for Treatment of Patients with GBM by Using a Novel DDS System for ASO
  • Shiro Akinaga, PhD - President and CEO, NANO MRNA, Co., Ltd.
10:15am - 10:55am
Networking Refreshment Break with Poster and Exhibit Viewing
Concurrent Conference Tracks
Showing 2 of 2 Streams
10:55am - 11:00am
Chairperson’s Remarks: Track 1
  • Hiroaki Suzuki - Key Account Manager Japan, Vetter Pharma International Japan
11:00am - 11:30am
Probing Chemical Space to Improve siRNA Therapeutic Profile
  • Mehran Nikan, PhD - Research Fellow, Ionis Pharmaceuticals
11:30am - 12:00pm
Development of Targeted RNA Therapeutics: Preclinical, Clinical Progress and Lessons Learned
  • Hanhua Huang, PhD - Vice President, Biology, Avidity Biosciences
12:00pm - 12:30pm
Advanced Manufacturing Partnerships: Innovative Solutions for Oligo Programs
  • Amanda Haas - Business Development Manager, Gene Editing Therapeutics, Agilent Technologies
10:55am - 11:00am
Chairperson’s Remarks: Track 2
  • Xinxin Gao, PhD - Principal Scientific Manager, Peptide Therapeutics, Genentech
11:00am - 11:30am
Revolutionizing Healthcare: Pioneering Peptide Innovations by AI Computational Design
  • Kerry Blanchard, MD, PhD - CEO, Chairman and Founder, Perpetual Medicines
11:30am - 12:00pm
Identification of Disulfide Constrained Peptide Based Binders against Membrane Bound E3 Ubiquitin Ligases
  • Xinxin Gao, PhD - Principal Scientific Manager, Peptide Therapeutics, Genentech
12:00pm - 12:30pm
First De-novo Designed Cyclic Peptides for SORT1 and CNS Delivery
  • Lucas Siow - CEO and Co-Founder, ProteinQure
12:30pm - 1:40pm
Networking Luncheon with Poster and Exhibit Viewing
Showing 2 of 2 Streams
1:40pm - 1:45pm
Chairperson's Remarks: Track 1
1:45pm - 2:15pm
Design and Selection of High-Affinity XenoAptamers for Diagnostic anbd Therapeutic Applications
  • Michiko Kimoto, PhD - Chief Operating Officer, R&D Director, Xenolis Pte. Ltd.
2:15pm - 2:45pm
Nitto Bispecific siRNA Targeting YAP1/WWTR1 As A Novel Therapeutic Agent for Liver Fibrosis
2:45pm - 3:15pm
Recent Progress of Kuxna's Antisense Oligonucleotide Therapeutics Platform and Application to Neurological Diseases
  • Hideaki Sato - President and CEO, Luxna Biotech
1:40pm - 1:45pm
Chairperson’s Remarks: Track 2
  • Markus Muttenthaler, PhD - Associate Professor, Neuropeptide Research, The University of Queensland and University of Vienna
1:45pm - 2:15pm
Program Update on Icotrokinra (JNJ-2113) in Psoriasis: The First-in-Class Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor
  • Steven Fakharzadeh, MD, PhD - Global Medical Affairs Leader Immunodermatology, Johnson & Johnson
2:15pm - 2:45pm
Oral Peptide Therapeutics for Gut Disorders
  • Markus Muttenthaler, PhD - Associate Professor, Neuropeptide Research, The University of Queensland and University of Vienna
2:45pm - 3:15pm
Biodegradable Silica Composite Technology Enabling Long-Acting Controlled Release of peptides
  • Frederic Dargelas, PhD - Senior Director, Head of Business Development and Alliance Management, DelSiTech Ltd.
3:15pm - 3:45pm
Networking Refreshment Break with Poster and Exhibit Viewing
Showing 1 of 1 Streams
3:45pm - 4:10pm
Discovery of Macrocyclic Peptide Inhibitors of SIRT7 and HDAC11
  • Christian Adam Olsen, PhD - Professor, Drug Design and Pharmacology, University of Copenhagen
4:10pm - 4:35pm
Preclinical Studies of Macrocyclic Peptides, Targeted Radiopharmaceutical Agents for PDL-1, Developed with 48Hour Discovery Pipeline
  • Ratmir Derda, PhD - Founder and CSO, 48 Hour Discovery, University of Alberta
4:35pm - 5:00pm
Combining Advanced Peptide Screening Methods to Identify Macrocyclic Peptide Candidates for Radiotherapy Development
  • Weiliang Xu, PhD - Associate Director of Business Development, PepLib
5:00pm - 5:25pm
Development of novel modality peptide drug: tissue regeneration-inducing medicine
  • Katsuto Tamai, M.D, PhD - CSO and Director of StemRIM Inc. and Guest Professor, Osaka University Graduate School of Medicine
5:25pm - 5:30pm
Close of Conference
Main Conference Day 2
Filter
Streams
Choose Day